Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric efgartigimod PH20 SC study in generalized myasthenia gravis
NL-OMON58707Phase 3Not yet recruiting
- Sponsor
- argenx
- Start
- Feb 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoints: Efgartigimod serum concentrations for model-driven dose confirmation and Pharmacodynamic parameters for PK/PD modeling. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON58707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58707.